Newron Pharmaceuticals S.p.A.
NP5
Classement en actions
#17693
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Prix de l'action
$10.40
Capitalisation boursière
$212.64M
Changement (1 jour)
1.09%
Changement (1 an)
-41.83%
Pays
IT
Échange Newron Pharmaceuticals S.p.A. (NP5)
Catégorie
Healthcare
Historique du prix de l'action pour Newron Pharmaceuticals S.p.A. (NP5)
Prix de clôture le plus élevé : $10.24 le 2026-10-01
Prix de clôture le plus bas : $31.91 le 2015-07-01
Prix de clôture le plus bas : $31.91 le 2015-07-01
Historique du prix de l'action de Newron Pharmaceuticals S.p.A. de 2015 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $537.25 | 25.98% |
US
|
|
| $195.62 | 628.57% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.90 | 8.32% |
NL
|
